ACCESS

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (ACCESS)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
200 patients (estimated)
Tags
Allogeneic Stem Cell Transplant, Myeloablative Conditioning (MAC), Nonmyeloablative Conditioning (NMA), Post-Allogeneic Stem Cell Transplant, Pre-Transplant, Reduced Intensity Conditioning (RIC)
Trial Type
Treatment
Last Update
2 months ago
SparkCures ID
1268
NCT Identifier
NCT04904588

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.